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Abstract
Reproductive factors have been linked to both breast cancer and DNA methylation, suggesting methylation as an important
mechanism by which reproductive factors impact on disease risk. However, few studies have investigated the link between
reproductive factors and DNA methylation in humans. Genome-wide methylation in peripheral blood lymphocytes of 376
healthy women from the prospective EPIC study was investigated using LUminometric Methylation Assay (LUMA). Also,
methylation of 458877 CpG sites was additionally investigated in an independent group of 332 participants of the EPIC-Italy
sub-cohort, using the Infinium HumanMethylation 450 BeadChip. Multivariate logistic regression and linear models were
used to investigate the association between reproductive risk factors and genome wide and CpG-specific DNA methylation,
respectively. Menarcheal age was inversely associated with global DNA methylation as measured with LUMA. For each
yearly increase in age at menarche, the risk of having genome wide methylation below median level was increased by 32%
(OR:1.32, 95%CI:1.14–1.53). When age at menarche was treated as a categorical variable, there was an inverse dose-response
relationship with LUMA methylation levels (OR12–14vs.#11 yrs:1.78, 95%CI:1.01–3.17 and OR$15vs.#11 yrs:4.59, 95%CI:2.04–
10.33; P for trend,0.0001). However, average levels of global methylation as measured by the Illumina technology were not
significantly associated with menarcheal age. In locus by locus comparative analyses, only one CpG site had significantly
different methylation depending on the menarcheal age category examined, but this finding was not replicated by
pyrosequencing in an independent data set. This study suggests a link between age at menarche and genome wide DNA
methylation, and the difference in results between the two arrays suggests that repetitive element methylation has a role in
the association. Epigenetic changes may be modulated by menarcheal age, or the association may be a mirror of other
important changes in early life that have a detectable effect on both methylation levels and menarcheal age.
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Introduction
In addition to genetic changes, epigenetic changes and
particularly DNA methylation can play an important role in the
aetiology of chronic diseases such as cancer [1–5]. Gene specific
promoter methylation can silence genes involved in critical cellular
processes such as cell cycle regulation, DNA repair or apoptosis.
At the same time, genome wide hypomethylation and in particular
reduced methylation in repetitive elements such as Long
Interspersed Nuclear Element-1 (LINE-1) and Alu repeats has
been associated with chromosomal instability and mutations
leading to chronic disease [1,3,4,6]. Methylation changes are
most evident in tissues such as tumour biopsies when compared to
normal tissue. However, genome wide methylation changes in
relation to disease have been observed in surrogate tissues such as
Peripheral Blood Leukocyte (PBL) DNA. Aberrant methylation in
PBLs has been previously associated with breast cancer [7,8],
colorectal adenoma [9,10], gastric cancer [11], head and neck
squamous cell carcinoma [12], and bladder cancer [13]. A recent
meta-analysis of all relevant studies has shown that there is overall
little evidence to support an association with cancer using
surrogate assays [14]. The exception has been one study based
on a large population-based case-control study, the Long Island
Breast Cancer Study Project, LIBCSP, with over 2,100 peripheral
blood samples, which revealed greater global and promoter
specific methylation in PBLs of breast cancer cases using LUMA
[15]. Although the potential influence of the disease onset on the
methylome of blood DNA needs to be tested, these results suggest
that methylation in PBLs DNA can serve as a biomarker for
chronic diseases such as cancer; it also points to a role of aberrant
methylation in carcinogenesis.
Environmental exposures influence epigenetic changes, includ-
ing methylation levels, particularly in utero and in early life [16,17].
In fact, genomic methylation has been shown to differ with respect
to several accepted disease risk factors. These include age, race,
anthropometric measures, environmental exposures and dietary
factors [18–22]. For example, a prudent dietary pattern charac-
terized by high intake of vegetables and fruit was shown to be
associated with a lower prevalence of genomic hypomethylation
(17, 19). Also, alcohol drinking and low dietary folate were found
to impact on genomic DNA methylation – genome wide and gene
specific [8,19]. In addition, in a multiethnic birth cohort in New-
York City [18], BMI was not found to be associated with DNA
methylation, but elsewhere, in women of childbearing age, a
higher BMI was associated with lower global methylation [23]. In
line with the latter finding, Zhang et al. [22] showed that higher
physical activity is associated with higher global methylation in a
cancer free population.
Reproductive factors were also shown to impact on global DNA
methylation. Terry et al. [18] showed that factors that impact on
breast cancer risk, including a greater birth height, a later age at
menarche, nulliparity, and a later age at first birth were associated
with higher global DNA methylation levels, but these results were
not replicated in other studies [8,24]. However, the studies that
investigate reproductive factors and epigenetic alterations are few
[25].
In the present study we aim to investigate the impact of a
number of reproductive variables on DNA methylation in PBLs of
healthy individuals. The relationship was first investigated with
genomic DNA methylation measurements using LUminometric
Methylation Assay (LUMA) in 376 women. LUMA is a cytosine
extension assay where the ratio of DNA CpG site cleavage by
methylation sensitive restriction endonucleases (HpaII) to the
cleavage from methylation insensitive endonucleases (MspI) is used
to determine % global methylation. HpaII cleavage occurs most
frequently in CpG island promoters and repetitive elements thus
methylation at these sites heavily influences the LUMA methyl-
ation estimate. Subsequently, to replicate the findings observed
with LUMA, whole genome methylation patterns were obtained
using Illumina 450 K in an independent group of 332 women.
The Illumina 450 K array covers 485,577 CpG sites, achieving a
high coverage of the entire genome, excluding repetitive elements.
Results
LUMA Methylation is Associated with Menarcheal Age
Demographic, anthropometric, lifestyle, and reproductive
characteristics for subjects included in Stage 1 are presented in
Table 1. The median LUMA genome-wide methylation in these
subjects was 71.7% and the standard deviation was 5.7%. Of all
the anthropometric measures and lifestyle variables examined,
only age at menarche was found to significantly differ across
quartiles of percent genome wide methylation (Table 2). Higher
genome wide methylation was associated with a younger age at
menarche (Kruskal-Wallis P-value=0.002), and this association
was significant even after Bonferroni correction for multiple testing
(Table 2). Age at blood collection, height, weight, BMI, physical
activity, smoking status, daily alcohol, folate consumption, age at
FFTP, menopausal status, parity, breastfeeding, oral contraceptive
(OC) use, hormone replacement therapy (HRT) use and highest
level of education achieved did not significantly differ between
subjects in methylation quartiles (Table 2).
The association between age at menarche and methylation was
further examined using logistic regression to adjust for potential
confounders. When median methylation was used as a cut off, 194
subjects had methylation below median levels and 182 had
methylation levels above median. Using these two classes, logistic
regression showed that age at menarche was significantly
associated with class occupancy. As shown in Table 3, for every
yearly increase in age at menarche, the risk of having below
median methylation was increased by 32% (OR: 1.32, 95%CI:
1.14–1.53). When age at menarche was treated as a categorical
Age at Menarche and DNA Methylation
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Covariate Metric Stage 1 Stage 2 Stage 3
(n=376)* (n=332)* (n=195)
Age Range 33.4–75.6 34–70 35–65
Median 52.7 54 49
Mean (SD
6) 52.9 (9.4) 52.5 (7.1) 49.4 (7.3)
Height Range 136.8–185.0 139.5–177.5 137.5–176.0
Median 160 159.3 159
Mean (SD) 160.1 (6.7) 159.0 (6.4) 158.7 (6.7)
Weight Range 39.6–110.2 42.8–106 44–103.5
Median 64.5 63.5 62
Mean (SD) 66.2 (11.2) 64.4 (11.2) 63.8 (9.8)
BMI
6
,25 kg/m
2 n (%) 182 (48.4) 164 (49.4) 98 (50.3)
25–30 kg/m
2 n (%) 141 (37.5) 118 (35.5) 7035.9)
$30 kg/m
2 n (%) 53 (14.1) 50 (15.1) 25 (12.8)
Physical Activity n( % ) Inactive: 34 (9.0)
n( % ) Moderately Inactive: 85 (22.6)
n( % ) Moderately Active: 210 (55.9)
n( % ) Active: 45 (12.0)
n( % ) Missing: 2 (0.5)
Range 1–5 0.5–30
Median 3 8.5
Mean (SD) 2.6 (0.8) 10.0 (6.9)
Smoking Status
Current Smoker n (%) 79 (21.1) 69 (20.9) 35 (17.9)
Former Smoker n (%) 65 (17.4) 66 (20.0) 48 (24.6)
Never n (%) 230 (61.5) 195 (59.1) 112 (57.5)
Daily alcohol consumption (g/day) Range 0–51.2 0–88.7 0–62.6
Median 3.5 1.9 3.3
Mean (SD) 6.5 (8.4) 8.7 (13.1) 9.6 (13.0)
Daily folate consumption (mg/day) Range 90.4–1113.0 45.3–586.2 52.6–644.8
Median 268.5 236.1 264.1
Mean (SD) 291.5 (107.9) 247.3 (82.0) 276.9 (95.4)
Age at Menarche
#11 yrs n (%) 72 (19.4) 62 (18.8) 47 (24.1)
12–14 yrs n (%) 242 (65.2) 233 (70.9) 134 (68.7)
$15 yrs n (%) 57 (15.4) 34 (10.3) 14 (7.2)
Age at FFTP
6
,25 yrs n (%) 147 (45.6) 118 (35.5) 65 (41.9)
25–30 yrs n (%) 131 (40.7) 118 (35.5) 69 (44.5)
.30 yrs n (%) 44 (13.7) 96 (29.0) 21 (13.6)
Parous
No n (%) 45 (12.0) 29 (8.8) 40 (20.5)
Yes n (%) 330 (88.0) 301 (91.2) 155 (79.5)
Breastfeeding
No n (%) 109 (30.0) 108 (32.7) 75 (48.4)
Yes n (%) 255 (70.0) 222 (67.3) 80 (51.6)
Menopausal Status
Premenopausal n (%) 175 (46.5) 155 (46.7) 90 (46.2)
Postmenopausal n (%) 201 (53.5) 177 (53.3) 105 (53.8)
Age at Menarche and DNA Methylation
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methylation levels: for the age category 12–14 compared to #11
years the OR was 1.78 (95% CI: 1.01–3.17), and for the age
category $15 compared to #11 years the OR was 4.59 (95% CI:
2.04–10.33) (P for trend,0.0001). These significant associations
persisted even after adjustment for relevant confounders: centre,
plate number, age at blood collection, height, weight, total
physical activity, smoking status, daily alcohol consumption, and
daily folate consumption.
Illumina 450 k Methylome Analysis Identifies an Epi-allele
Associated with Menarcheal Age
In the second population group, 329 subjects (out of 332) had
available information on age at menarche (Table 1). In contrast to
LUMA global methylation, the median genome-wide methylation
level using the 450 k ILLUMINA assay did not significantly differ
between menarcheal age groups. Similarly, CpG island methyl-
ation and promoter methylation were not significantly different
between subjects in different menarcheal age categories. However,
there was a trend towards decreasing methylation with increasing
age at menarche, consistent with the LUMA results (Figure 1).
When adjusting for case-control status, age, and position on the
chip in a linear regression model with methylation M-values as a
continuous outcome, and age at menarche as a categorical
variable (.11 yrs vs. #11 yrs), age at menarche was significantly
associated with methylation in a single CpG site (cg01339004),
located on the body of the SMAD6 gene (p,1.00610
27, genome-
wide level significance) (Table 4, Figure 2). When only those
subjects that remained healthy for at least 5 years following
recruitment and blood collection were analysed, the same CpG
site was found to be significantly associated with age at menarche
(p=6.71610
28).
However, using bisulphite Pyrosequencing for the SMAD6
cg01339004 locus, we were unable to replicate this finding in an
independent sample set using a generalized linear model while
adjusting for the same confounders (n=185, p=0.07). Wilcoxon
rank sum non-parametric test also did not reveal significantly
differential methylation between the two age at menarche
categories (p=0.082) measured using bisuphite pyrosequencing
(Figure 2).
Discussion
In this study, age at menarche was negatively associated with
LUMA genome wide methylation in a statistically significant
manner. The association of genome wide methylation with
menarcheal age was the only strong and consistent association
we found and remained unaltered after adjustment for relevant
confounders. Previous study results on age at menarche and
methylation were conflicting. Terry et al. [18] found that a later
age at menarche was associated with higher genomic global
methylation later on in adulthood, but DNA methylation was only
assessed in 92 individuals and the authors used a different
technique for measuring global methylation ([
3H]-methyl accep-
tance assay). On the other hand, Choi et al. [8] did not
demonstrate a statistically significant association between menar-
cheal age and global DNA methylation using LINE1 methylation
as a surrogate for global methylation.
The negative association between LUMA methylation and later
age at menarche is counter-intuitive because (a) a later age at
menarche is known to protect from breast cancer, and (b) lower
global methylation is expected to increase genome instability and
thus increase cancer risk [8,26]. However, our observation is
consistent with the findings in the LIBCSP study, where breast
cancer was associated with increased genome wide methylation as
measured with LUMA [15]. This apparent paradox could be
explained by LUMA’s characteristics, i.e. broad coverage in CpG
dense regions, such as promoters, and decreased coverage in the
remaining genome [27]. Another potential explanation is that
aberrant methylation associated with age at menarche is unrelated
to the methylation changes relevant to breast cancer, or that the
association with age at menarche is in fact confounded by other
determinants of methylation levels.
Given the conflicting reports in the literature [8,15,18], we
aimed to replicate, in a dataset with whole genome methylation
data, the association between age at menarche and DNA
methylation that we observed with the LUMA technology. This
was done by using the robust Illumina technology. This approach
also enabled the identification of specific genes that might be
involved in the mechanistic pathways linking menarcheal age with
disease. In contrast to the findings of LUMA, genome wide
methylation in this second dataset did not significantly differ
between subjects in different menarcheal age groups. However,
there was a non-significant trend towards decreasing methylation
with increasing age at menarche, consistent with the LUMA
findings (Figure 1). The lack of association in this dataset could be
caused by differences in coverage between the two assays used.
LUMA assesses methylation of a specific restriction enzyme site
(HpaII, CCGG), which occurs most frequently in CpG island
promoters – also covered by the 450 K array – but also in
repetitive elements. However, the Infinium HumanMethylation
450 BeadChip, due to its probe design, does not interrogate
Table 1. Cont.
Covariate Metric Stage 1 Stage 2 Stage 3
(n=376)* (n=332)* (n=195)
HRT
6 use
Ever n (%) 29 (7.8) 13 (3.9) 34 (17.4)
Never n (%) 343 (92.2) 317 (96.1) 158 (81.0)
OC
6 use
Ever n (%) 176 (46.9) 131 (39.7) 94 (48.2)
Never n (%) 199 (53.1) 199 (60.3) 101 (51.8)
*Failure of category counts to add up to this value denotes missing values.
6SD: Standard Deviation, BMI: Body Mass Index, FFTP: First Full Term Pregnancy, HRT: Hormone Replacement Therapy, OC: Oral Contraceptive.
doi:10.1371/journal.pone.0079391.t001
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(Stage 1).
Variable Methylation Quartile: Cut-offs
1: 23.0–68.4% 2: 68.5–71.7% 3: 71.8–74.0% 4: 74.1–80.0% p-value
a
Units (n=103) (n=91) (n=93) (n=89)
Age at blood collection Mean 6 SD 52.968.5 52.268.5 53.1610.0 53.6610.7 0.863
Height Mean 6 SD 159.066.1 160.766.4 160.866.7 160.067.5 0.424
Weight Mean 6 SD 66.0612.3 66.5610.5 64.8611.3 67.7610.4 0.316
BMI
6 Mean 6 SD 26.265.1 25.864.1 25.164.4 26.564.4 0.112
Physical Activity
Inactive N, (%) 4 (3.9) 9 (9.9) 11 (11.8) 10 (11.2)
Moderately Inactive N, (%) 29 (28.2) 22 (24.2) 16 (17.2) 18 (20.3)
Moderately Active N, (%) 60 (58.3) 45 (49.4) 54 (58.1) 51 (57.3)
Active N, (%) 9 (8.7) 15 (16.5) 11 (11.8) 10 (11.2)
Missing N, (%) 1 (0.9) 0 (0.0) 1 (1.1) 0 (0.0) 0.404
Smoking Status
Current Smoker N, (%) 58 (56.3) 59 (64.8) 49 (52.7) 47 (52.9)
Former Smoker N, (%) 23 (22.3) 12 (13.2) 20 (21.5) 22 (24.7)
Never N, (%) 22 (21.4) 20 (22.0) 23 (24.7) 19 (21.3)
Unknown N, (%) 0 (0.0) 0 (0.0) 1 (1.1) 1 (1.1) 0.596
Alcohol consumption –lifetime
average (g/day)
Mean 6 SD 7.068.6 6.969.7 5.466.4 6.768.6 0.822
Dietary folate intake (g/day) Mean 6 SD 294.66121.9 276.9696.7 293.16104.2 301.06105.3 0.386
Age at menarche Mean 6 SD 13.261.7 13.361.7 12.561.4 12.861.7 0.002*
Age at FFTP
6 Mean 6 SD 25.363.5 26.263.9 24.864.0 25.063.7 0.132
Menopausal Status
Pre N, (%) 42 (40.8) 47 (51.6) 46 (49.5) 40 (44.9)
Post N, (%) 60 (58.3) 43 (47.3) 45 (48.4) 49 (55.1)
Surgical Post N, (%) 1 (0.9) 1 (1.1) 2 (2.1) 0 (0.0) 0.545
Parous
No N, (%) 12 (11.7) 7 (7.7) 13 (14.0) 19 (21.3)
Yes N, (%) 90 (87.4) 84 (92.3) 79 (84.9) 70 (78.7)
Unknown N, (%) 1 (0.9) 0 (0.0) 1 (1.1) 0 (0.0) 0.075
Breastfeeding
No N, (%) 30 (29.1) 19 (20.9) 26 (28.0) 34 (38.2)
Yes N, (%) 70 (68.0) 70 (76.9) 62 (66.7) 53 (59.6)
Unknown N, (%) 3 (2.9) 2 (2.2) 5 (5.3) 2 (2.2) 0.086
OC
6 use
No N, (%) 50 (48.5) 53 (58.2) 47 (50.5) 49 (55.1)
Yes N, (%) 53 (51.5) 38 (41.8) 46 (49.5) 39 (43.8)
Unknown N, (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.1) 0.512
HRT
6 use
No N, (%) 93 (90.3) 84 (92.3) 81 (87.1) 85 (95.5)
Yes N, (%) 3 (2.9) 6 (6.6) 10 (10.7) 4 (4.5)
Unknown N, (%) 7 (6.8) 1 (1.1) 2 (2.2) 0 (0.0) 0.399
Highest Education
None N, (%) 10 (9.6) 6 (6.6) 7 (7.4) 6 (6.8)
Primary N, (%) 45 (43.7) 41 (45.1) 36 (38.7) 35 (39.3)
Technical/Professional N, (%) 15 (14.6) 9 (9.9) 18 (19.4) 20 (22.5)
Secondary N, (%) 12 (11.7) 21 (23.1) 17 (18.3) 17 (19.1)
Age at Menarche and DNA Methylation
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in many cases of neoplasia [28,29]. For example, satellite and
SINE repeats were found to be enriched with hypomethylated
Differentially Methylated Regions (DMRs) whereas LINE was
enriched with hypermethylated DMRs in malignant peripheral
nerve sheath tumours compared to normal Schwann cells [30]. If
age at menarche is related to methylation patterns in these
repetitive elements, the hypomethylation would not have been
evident in the 450 K chip but it would have been detected in the
LUMA assay. This suggests that the LUMA based association is
being driven largely by methylation differences in repetitive
elements, where age at menarche could have a greater effect.
In the locus by locus analysis, methylation of a single CpG site
was shown to be associated with age at menarche. However, in an
independent sample set, this finding was not replicated. Given the
multiple comparisons in the locus by locus analyses in the Illumina
dataset, one cannot rule out the possibility that this finding is the
result of chance, and given that the independent sample set did not
replicate this finding using an alternative method, we conclude
that it is likely to be a false positive association. However, further
validation in further independent data sets, with a greater sample
size may increase the power sufficiently to detect possible
associations between methylation of individual loci and age at
menarche.
The mechanistic link which could explain the association
between menarcheal age and genome-wide DNA methylation, but
not in individual CpG loci is yet to be determined. However,
endogenous oestrogen exposure is a strong candidate for
epigenetic changes since an earlier age at menarche exposes a
woman to a greater cumulative amount of endogenous oestrogens
Table 2. Cont.
Variable Methylation Quartile: Cut-offs
1: 23.0–68.4% 2: 68.5–71.7% 3: 71.8–74.0% 4: 74.1–80.0% p-value
a
Units (n=103) (n=91) (n=93) (n=89)
University N, (%) 12 (11.7) 13 (14.3) 14 (15.1) 10 (11.2)
Unspecified N, (%) 9 (8.7) 1 (1.0) 1 (1.1) 1 (1.1) 0.264
aFor continuous variables, P-value was derived from Kruskal-Wallis test. For categorical variables, P-value was derived from a chi square test, with the exclusion of
‘‘Unknown’’ categories due to their small cell counts. Both reflect the association between quartiles of methylation and the investigated variables.
*Significant at the Bonferroni-corrected significance cut off (P=0.003) for multiple comparisons.
6BMI: Body Mass Index, FFTP: First Full Term Pregnancy, HRT: Hormone Replacement Therapy, OC: Oral Contraceptive.
doi:10.1371/journal.pone.0079391.t002
Table 3. Logistic Regression for percent genome wide methylation (LUMA levels below vs. above median) by age at menarche as
a categorical variable and other relevant confounders.
Variable
Methylation
Median ± SD Adjusted OR
a 95% Confidence Interval P-value
Center NA 0.99 0.97–1.02 0.518
Plate number NA 0.94 0.80–1.10 0.400
Age at blood collection (continuous) NA 0.98 0.96–1.00 0.254
Height (continuous in cm) NA 0.98 0.95–1.01 0.354
Weight (continuous in kg) NA 1.01 0.98–1.03 0.453
Total physical activity index – sex specific
(continuous activity categories)
NA 1.03 0.78–1.37 0.813
Smoking status
Never 71.6266.25 1.00
Past smoker 72.1864.51 0.85 0.46–1.55 0.592
Current smoker 70.7365.17 0.98 0.56–1.72 0.954
Daily alcohol intake (continuous in g/day) NA 1.01 0.99–1.04 0.354
Daily folate intake (continuous in mg/day) NA 1.00 0.99–1.00 0.863
Age at menarche (continuous in years) NA 1.32 1.14–1.53 ,0.0001*
Age at menarche (categorical)
#11 years old 72.5964.49 1.00
12–14 years old 71.6265.93 1.78 1.01–3.17 0.048*
$15 years old 70.1266.33 4.59 2.04–10.33 ,0.0001*
P for Trend ,0.0001*
aEach OR is adjusted for all other variables in the table.
*Significant at the 0.05 level.
doi:10.1371/journal.pone.0079391.t003
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oestrogen impacts on DNA methylation. More specifically it was
shown that oestrogen receptor (ER) positive breast tumour tissues
have differential methylation at several CpG loci compared to ER
negative tumours [24,31] and oestrogen induced breast tumours
have differential DNA methylation patterns in ACI rat mammary
gland tissue [32]. Further investigation into the role of oestrogen
on repetitive element methylation is, therefore, warranted.
It is also possible that age at menarche is an indirect indicator of
other macroscopic changes that may impact on DNA methylation.
Table 4. Significant CpG sites in a linear regression model.
TargetID P-value
/ Q-value
?
Regression
Coefficient
<
Chromosome
number Gene
CpG Position
Relative to Gene CpG Island’s Name
cg01339004 8.83E-08 0.0392 20.2765 15 SMAD6 Body NA
Methylation treated as a continuous outcome (M-values: PBC and COMBAT on chip) and menarcheal age category (.11 vs. #11 years) treated as a categorical exposure.
Adjusting for age at blood collection, case-control status, and position on the chip.
Analysis of all subjects or of only the 240 subjects that remained healthy for at least 5 years following recruitment yielded the same results.
/P value from a liner regression model where methylation is treated as a continuous outcome (M-values: PBC and COMBAT on chip) and the effect of age at menarche
as a categorical variable (.11 vs. #11 years), adjusted for age, case-control status, and chip position.
?Q value: False Discovery Rate (FDR) corrected P-value.
<The regression coefficient for each probe; change in methylation for having an age at menarche .11 years vs. #11 years.
doi:10.1371/journal.pone.0079391.t004
Figure 1. Boxplots of median genome-wide methylation between the three menarcheal age categories. A: Median % global
methylation as measured with LUMA in Stage 1. Bi. Genome-wide methylation across all probes (averaged per individual). Bii. Genome-wide
methylation across probes on CpG islands (averaged per individual). Biii. Genome-wide methylation across probes on promoter regions (averaged per
individual). M
¤=Median methylation value. p=p value from Wilcoxon rank-sum test comparisons.
doi:10.1371/journal.pone.0079391.g001
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of the epigenetic system to environmental factors is heightened
during periods of developmental plasticity such as childhood,
adolescence and puberty [17]. Epigenetic modifications in
response to environmental exposures at these critical periods are
often subtle initially and even though they do not lead to
phenotypic changes at the time of exposure, they may lead to
increased risk of dysfunction and disease later on in life [17].
Trends in the past decades show a rapid shift towards an earlier
age at menarche and this is more pronounced in developed
countries [33]. This trend is too steep to be attributed to genetic
changes. Instead, environmental exposures at the periods of
developmental plasticity are likely to be the cause of the dramatic
decrease in age at menarche. For example, childhood obesity
disrupts the hormonal milieu leading to an increase in adipocyte
secreted leptin, or in adrenal secreted androgens, all of which
impact on menarcheal onset [34]. Pre or neo-natal nutrition as
well as early life exposure to endocrine disrupting chemicals
(EDCs) can also lead to hormonal imbalances impacting on age at
menarche [17]. Given that these exposures occur at the periods
when the epigenetic signature is more plastic, they might also lead
to aberrant DNA methylation changes which will be inherited
during cell divisions and be detectable years later. Therefore, the
aberrant DNA methylation pattern observed in adulthood might
not be related to menarcheal age per se but to an early life
environmental exposure, like diet, that impacts both on age at
menarche and on DNA methylation.
This study suggests an association between age at menarche and
DNA methylation. All samples in this study were collected prior to
the onset of disease, and the changes observed were present in the
blood of individuals when they were still healthy, at least five years
prior to their diagnosis, limiting the potential influence of the
presence of cancer (reverse causality) on the methylome of blood
DNA. In addition, the sample sizes examined –376 subjects for
LUMA and 332 subjects for Illumina 450 K Methylation are fairly
large datasets, allowing for sufficient power to detect significant
methylation changes if present. However, one important limitation
of our study was the lack of information on other early life
exposures, therefore it was impossible to investigate whether such
exposures confound the observed association between age at
menarche and DNA methylation. Thus, this hypothesis needs to
be further investigated in birth cohorts.
Overall, our results suggest that DNA methylation changes,
particularly in repetitive elements, may be associated with
menarcheal age. However, it is also possible that some important
changes taking place in early life and which are associated with age
at menarche – in particular nutrition – have a detectable effect on
methylation levels.
Figure 2. Analysis of SMAD6 cg01339004 probe methylation. Ai: Boxplot of b-value methylation of cg01339004 probe as measured with
Illumina 450 k beadchip in Stage 2. Aii: Boxplot of methylation level of cg01339004 probe as measured with bisulphite pyrosequencing in Stage 3. B:
Volcano plot: Difference in median methylation between the two menarcheal age groups (.11 (n=268) vs. #11 years, (n=62), against the –log(P-
Value) of a linear regression analysis with methylation as a continuous outcome (M-values) and age at menarche (.11 vs. #11 years) as a categorical
exposure, adjusting for age, case-control status, and chip position. C. Q-Q plot on P-values from a linear regression analysis with methylation as a
continuous outcome (M-values) and age at menarche (.11 vs. #11 years) as a categorical exposure, adjusting for age, case-control status, and chip
position.
doi:10.1371/journal.pone.0079391.g002
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Stage 1: Genome Wide Methylation with LUminometric
Methylation Assay (LUMA)
Study participants. All participants signed an informed
consent and the study protocol was approved by the Ethics
Committee of the International Agency for Research on Cancer.
Epidemiologic data and blood samples collected from the
European Prospective Investigation into Cancer and Nutrition
(EPIC) were used. EPIC is an ongoing study designed to
investigate diet, nutrition, lifestyle and environmental factors with
respect to cancer incidence. The cohort consists of 519,978
participants from 23 centres in 10 European countries - Denmark,
France, Germany, Greece, Italy, the Netherlands, Norway, Spain,
Sweden and the United Kingdom. Information on lifestyle, diet,
anthropometric measures and environmental exposures were
collected using questionnaires at recruitment and were standard-
ized across the different participating centres. Blood was also
collected from the majority of subjects at recruitment [35]. For the
LUMA investigation, 600 individuals – half breast cancer cases
and half controls – from the EPIC cohort were chosen. Of these,
77 subjects were initially excluded: 1 subject was a duplicate, there
was not enough DNA for 24 subjects, and 52 samples produced no
or a weak signal. Of the remaining 523 subjects with reliable
measurements, we investigated 376 women in this specific study,
who remained free of cancer for at least 5 years following blood
collection.
Genome wide DNA methylation. LUMA was used to
quantify genome wide methylation levels [27,36] in PBLs in the
blood of subjects, collected at recruitment. Genomic DNA was
extracted using standard protocols. LUMA gives a measure of %
global methylation using the ratio of DNA cleavage by methyl-
ation sensitive (HpaII) and methylation insensitive (MspI) restric-
tion enzymes. In LUMA, polymerase extension assay by
Pyrosequencing is employed to determine cleavage. The LUMA
method was validated using DNA controls of known DNA
methylation status [37]. In the assay, 5-Aza-dC treated and CpG
methylated Jurkat genomic DNA (New England Biolabs, Ipswich,
MA) were used as methylated and unmethylated control samples.
Genome wide methylation is expressed as a percentage obtained
from the equation [37]:
GenomewideMethylation(%)
~½1{((HpaII
X
G=
X
T)7(MspI
X
G=
X
T)) |100:
Statistical analyses. We first compared the distribution of a
number of anthropometric measures, reproductive factors, and
lifestyle characteristics such as age at blood collection, height,
weight, parity, age at first full term pregnancy, breastfeeding and
hormone use across quartiles of percent global methylation. The
quartile cut offs were the 25
th,5 0
th, and 75
th percentile
methylation values in controls. For continuous variables, the
non-parametric equivalent of one-way analysis of variance
(ANOVA), the Kruskal-Wallis test, was used as genome wide
methylation was not normally distributed. For categorical
variables, chi-square test was used.
The reproductive variables that were statistically differentially
distributed between methylation quartiles were investigated
further. The resulting profile of genome wide methylation
distribution was skewed and several transformations failed to
normalize it. In addition, various GLM models investigated failed
to adequately describe the outcome distribution. As a result, the
methylation outcome was dichotomized – above and below
median methylation – and unconditional logistic regression was
used to evaluate the association between exposure variables and
DNA methylation, the latter being the dependent variable. All
significant variables were included both as continuous and
categorical when relevant (e.g. age at menarche #11 y, 12–14 y,
$15 y). Based on the available literature, the logistic regression
model was fully adjusted for centre, plate number, age at blood
collection, height, weight, total physical activity, smoking status,
daily alcohol consumption, and daily folate consumption. All
confounders were entered into the model as continuous variables
with the exception of smoking status which was treated as
categorical – past, never, present.
All analyses were performed using STATA (Release 11; College
Station, TX: StataCorp LP).
Stage 2: Locus-by-locus Analysis with Illumina 450 K to
Replicate the Findings of LUMA Genome Wide
Methylation Analysis
Study participants. All participants signed an informed
consent and the study protocol was approved by the ethics
committee of the Human Genetics Foundation (HuGeF).
The EPIC Italy sub-cohort consists of 32,578 female subjects
recruited from 5 different centers – Varese, Turin, Florence,
Naples, and Ragusa. From this subcohort, 166 breast cancer cases
and 166 controls, matched on date of birth (65 years), seasonality
of blood draw, and date of recruitment were selected. However,
since for this investigation case/control status is not the outcome
and since at the time of blood collection all individuals were
healthy, all 332 blood samples were treated as healthy blood.
Nevertheless, given the long latency period of neoplasia, analyses
were carried out on all subjects with age at menarche information
(n=329) as well as on only the subjects that remained healthy at
least 5 years following recruitment and blood collection (n=240).
Illumina 450 K methylation. DNA was extracted from
buffy coats or blood cell fractions using the QIAsymphony DNA
Midi Kit (Qiagen, Crawley, UK). 500 ng of DNA was bisulphite-
converted with the EZ-96 DNA Methylation-Gold
TM Kit, used
according to the manufacturer’s protocol (Zymo Research,
Orange, CA, USA). Next, the 450 K DNA methylation array by
Illumina (Infinium HumanMethylation 450 BeadChip) was
performed on 4 ml of bisulphite-converted DNA, following the
Illumina Infinium HD Methylation protocol. This array includes
485,577 cytosine positions of the human genome (482,421 CpG
sites (99.4%), 3091 non-CpG sites and 65 random SNPs; hereafter
the term CpG will be used to refer to all of these, unless otherwise
specified). Briefly, a whole genome amplification step was followed
by enzymatic end-point fragmentation and hybridization to
HumanMethylation 450 BeadChips at 48uC for 17 h, followed
by single nucleotide extension. The incorporated nucleotides were
labelled with biotin (ddCTP and ddGTP) and 2,4-dinitrophenol
(DNP) (ddATP and ddTTP). After the extension step and staining,
the BeadChip was washed and scanned using the Illumina HiScan
SQ scanner. The intensities of the images were extracted using the
GenomeStudio (v.2011.1) Methylation module (1.9.0) software,
which normalizes within-sample data using different internal
controls that are present on the HumanMethylation 450
BeadChip and internal background probes. The Infinium
HumanMethylation 450 BeadChip data, for subjects with age at
menarche information, were made available on the data repository
Gene Expression Omnibus (GEO), with accession number
GSE51057.
Statistical analyses. Methylated and unmethylated intensi-
ties for each probe were provided by GenomeStudio software. In
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detection p-values were also provided by GenomeStudio software
(Illumina). The detection values indicate the confidence that can
be placed on a b-value reading. As a first step, all readings with a
p-value.0.05 were considered as non-detected so as to not
influence downstream pre-processing and analyses.
Background noise correction was then performed as back-
ground fluorescence can contribute an additive error to each
signal intensity leading to a reduced dynamic range for the
methylation reading. Given that signal intensities can be red or
green, and given the technical variation in fluorescent signal
depending on the intensity colour, dye bias also had to be taken
into account using the method described by Triche et al. [38]. The
analysis of other classical quality control measures (such as
staining, extension, hybridization, or bisulphite conversion)
provided by GenomeStudio did not reveal any major quality
issues.
The methylated and unmethylated intensities provided by
GenomeStudio were used to calculate methylation b-values based
on the equation:
Beta(b)~max(M,0)
max(M,0)zmax(U,0)z100
where M is the intensity of the methylated signal and U the
intensity of the unmethylated signal at each probe.
Beta values were later peak based corrected (PBC) as suggested
by Dedeurwaerder et al. [39] in order to correct for the bias
arising from the two different probe designs on the array. In order
to correct for batch effects, COMBAT was then used [40,41].
Lastly, missing data were imputed using KNN (k-nearest
neighbours) method once, implemented in knn.impute function
from R-CRAN.
In order to replicate the results observed with LUMA,
methylation beta values across all probes were averaged per
individual to derive a measure of genome-wide methylation per
subject. Similarly, probes in CpG islands and promoter regions
were averaged per subject. Wilcoxon-rank sum tests were
performed to examine whether genome-wide, CpG island and
promoter methylation was significantly different between subjects
in the three menarcheal age groups examined with LUMA
(#11 y, 12–14 y, $15 y).
In addition, locus by locus analysis of methylation was
performed using a linear regression model. Quantile normaliza-
tion was performed prior to regression using the R package
‘‘preprocessCore’’ from Bioconductor. In order to satisfy the
normality assumptions of a linear regression model, beta
methylation values were converted to M-values as described in
[42] and entered into the model as a continuous outcome. M-
values were also peak based corrected and COMBAT adjusted for
chip number to correct for batch effects. Only age at menarche,
the only significant reproductive variable in LUMA analysis, was
investigated here. Age at menarche was treated as a categorical
outcome (#11 yrs vs. .11 yrs). This categorization was chosen
since in the LUMA data, both menarcheal age categories above
11 yrs old were significantly associated with methylation when
compared to a menarcheal age of #11 years.
Q-values, measuring the maximum False Discovery Rate (FDR)
from the Benjamini and Hochberg method were derived for each
probe analysis, and overall Type I error was controlled for by
conservatively applying Bonferroni multiple testing correction.
The per-test significance cut-off value was set to 1.00610
27. The
analysis was performed first on all 329 subjects with age at
menarche information and then repeated only on the 240 subjects
that remained healthy for at least five years following recruitment.
The linear model was adjusted for age, case-control status and
chip position. All confounders were entered into the model as
continuous variables with the exception of chip position.
Stage 3: Single Locus (SMAD6, cg01339004)
Pyrosequencing Analysis to Replicate the Findings of
Locus by locus Illumina 450 K Analysis
Study participants. The participants used in this stage were
also subjects of the EPIC Italy sub-cohort. One hundred ninety-
five women, with available information on age at menarche, were
selected for bisulphite pyrosequencing based on sample availability
from other studies. Eight of these subjects overlapped with the
subjects used in Stage 2.
Bisulphite Pyrosequencing was used to quantify CpG specific
methylation at the SMAD6 locus in these individuals using
standard protocols [43]. The primers used for cg01339004 were
Forward ([BIOTIN]–TGGTATAGTAGTGGTTTGGTATAA-
GAT), Reverse (TACCACCCACCCATTCACTCTATAA) and
Sequencing Primer (TCTATAAATAAACAAACTAAAACC).
Statistical analyses. Out of the 195 samples analysed, for 10
samples the pyrosequencing results did not pass quality check.
Wilcoxon rank sum non-parametric test was performed to
examine whether SMAD6 cg01339004 methylation was different
between age at menarche categories (#11 vs. .11 years). In
addition, a generalized linear regression model with SMAD6
cg01339004 methylation as a continuous outcome and with age at
menarche as a categorical variable (#11 vs. .11 years) was run to
correct for confounding variables – age at blood collection and
case-control status – as in the case of the Illumina 450 K analysis.
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